Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome | Blood | American Society of Hematology
Publisher’s Note: There is a Blood Commentary on this article in this issue.
Related Articles
Age-Adjusted Dosing of Fludarabine for Lymphodepletion in CAR T-cell Therapy: A Clinical Trial Simulation Study
Key Points. This study shows that age-based fludarabine dosing can increase the number of individuals within a predefined cumulative AUC range.Age-based or
A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD
Key Points. In NHPs, a single CD137-ADC dose post-HCT eliminates PD-1+ effector T-cells, enabling reconstitution of non-pathogenic T-cell subsets.The CD137
Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome
Key Points. Somatic preleukemic GATA1s mutations are acquired before birth in 25% of neonates with Down syndrome and are not acquired post-natallyRates of
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Key Points. Matched allogeneic donor CD19CAR-T (CAR-DLI) is safe and effective for relapsed adult B-ALL but only following pre-CAR-T lymphodepletion.Repeat
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens
Key Points. BCMA antigen expression is controlled by the ubiquitin-proteasome system in a p97-dependent manner at the plasma membraneElevation of BCMA cell
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma
Key Points. Sequential treatment with commercially available BCMA-directed CAR-T therapy in refractory myeloma is safe and efficaciousDuration of response
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Key Points. Mutations in distinct RAS-pathway genes have unique clonal architecture and cooperate with other genomic events to drive outcomes in CMML.Refin
Paper: A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical a nd Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad…
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Abstract. Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma
Bispecific antibodies (BsAbs) create an immunologic synapse between T cells and malignant cells, via T-cell surface marker CD3 and a tumor cell surface marker, activating…